Ming-chu Hsu

Biography

Founded in 2001 with headquarters in Taiwan and a wholly-owned Beijing subsidiary, TaiGen Biotechnology Co., Ltd. is involved in the development of novel pharmaceuticals, from discovery to clinical development. TaiGen has experience in regulatory submission with international drug approval agencies, including US FDA and China CFDA Class 1.1 IND submission and approval, and in performing multi-center, multi-national clinical trials. TaiGen drugs and patents are 100% owned by the company, with drugs in the pipeline for infectious diseases, cancer and diabetes-related complications. TaiGen has a consistently high volume of research output, with a new FDA IND submitted at least every 3-4 years. Currently the company holds over 200 drug patents covering all the major world pharmaceutical markets. TaiGen investors include YFY Group, Taiwan's National Development Fund, Taiwan Sugar Corporation, Yaohua Glass and other government-owned companies as well as finance and insurance companies. In January 2014, through its holding company TaiGen Biopharmaceutical Holdings Limited, TaiGen became a publically listed company on Taiwan's GreTai stock market as F*Taigen, with ticker number 4157

Research Interest

Biopharmaceutical